Small molecule · Inhibitor of PRMT5 · developed by IDEAYA Biosciences
IDE892 is an orally bioavailable, methylthioadenosine (MTA)-selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It binds PRMT5 when it is complexed with MTA, a complex elevated in MTAP-deleted cancer cells, reducing histone arginine methylation and proliferation in those cells. It is being studied in advanced or metastatic cancers harboring MTAP deletions.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07277413 | Phase 1 | NSCLC Adenocarcinoma | Recruiting | IDYA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Adenocarcinoma of EsophagusBiliary Tract CarcinomaBladder CancerGastric AdenocarcinomaGastroesophageal Cancer (GC)MesotheliomaNon-Small Cell Lung Cancer NSCLCNSCLC AdenocarcinomaPancreatic CancerPeritoneal MesotheliomaPleural MesotheliomaSquamous Cell Car. - EsophagusUrothelial Carcinoma (UC)
Updated Oct 18, 2026. Something wrong or missing? Report it on the IDYA page.
See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IDYA catalysts and pipeline →